RESUMO
To further improve the output performance of triboelectric devices, reducing charge attenuation and loss has become a hot research topic. Particularly, textiles have emerged as one of the promising research directions for triboelectric devices owing to their special internal structure and large specific surface area. In the present work, polyacrylonitrile fibers are fabricated with two distinct structures to provide a higher dielectric constant due to the strong polar properties brought about by higher dipole moment of the CN group. In addition, the complex and closely connected structure of the textile increases specific internal surface area. As a friction layer, the output voltage is shown to increase to 625% of the initial value (from 8 to 60 V) after the application of friction for a short time due to accumulation property. When acting as a trapping layer, the charge loss after injection is effectively prevented due to excellent charge trapping effect. After 24 h, the triboelectric output performance remains at ≈70% of the initial value (decreasing from 320 to 220 V), which is more than 20 times that of the polytetrafluoroethylene film, which decreases from 125 to 19 V. The device is realized for the advanced application of multi-modal sensors.
RESUMO
PURPOSE: The aim of this retrospective study was to identify the reliable long term prognostic factors in patients with stage II/III breast cancer who were treated with an adjuvant extension of neoadjuvant chemotherapy (NC). METHODS: Women under the age of 70-years, with previously untreated clinical stage II and III breast cancer, were treated with NC, which was comprised of three cycles of FEC (5-FU, epirubicin, and cyclophosphamide every 3 weeks) or MMM (methotrexate, mitoxantrone, and mitomycin-C every 3 weeks) with an adjuvant extension of three cycles of the same regimen. RESULTS: Cumulative 10-years disease-free survival (DFS) was 87.3% for patients with a good response and 55.5% for patients with no response (p=0.032); 92.9% for node negative patients, 75.0% for 1-3 positive nodes, 50.0% for 4-9 positive nodes and no survival for 10 or more positive nodes (p<0.001). Cumulative 10-years overall survival (OS) was 89.1% for patients with good response and 55.5% for patients with no response (p=0.024); 95.2% for node negative patients, 80.0% for 1-3 positive nodes, 50.0% for 4-9 positive nodes and no survival for 10 or more positive nodes (p<0.001). No significant difference was observed in DFS and OS between the FEC and MMM treated groups. CONCLUSION: Based on a review of data with a long follow-up, only the clinical response to NC and the absolute number of metastatic axillary lymph node identified at surgical staging were independent predictors of both DFS and OS in patients with stage II/III breast cancer patients treated with adjuvant extension of NC.